Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
about
Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roadsAnti-angiogenesis and metastasis: a tumour and stromal cell allianceWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesBroad targeting of angiogenesis for cancer prevention and therapyMouse models for studying angiogenesis and lymphangiogenesis in cancerThe ever-expanding role of HIF in tumour and stromal biologyAdverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Chromatin association of XRCC5/6 in the absence of DNA damage depends on the XPE gene product DDB2.A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinomaTumor-penetrating iRGD peptide inhibits metastasis.Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis.VEGF dose regulates vascular stabilization through Semaphorin3A and the Neuropilin-1+ monocyte/TGF-β1 paracrine axisRecurrent oral cancer: current and emerging therapeutic approaches.Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumorsThe axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors.Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.A novel podocyte gene, semaphorin 3G, protects glomerular podocyte from lipopolysaccharide-induced inflammation.Axon guidance molecule semaphorin3A is a novel tumor suppressor in head and neck squamous cell carcinomaInhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic miceEverolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.Controlling escape from angiogenesis inhibitors.Semaphorin3a signaling, podocyte shape, and glomerular disease.Class 3 semaphorins as a therapeutic target.Quantitative mass spectrometry-based proteomics in angiogenesis.Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies.The role of semaphorins and their receptors in vascular development and cancer.Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.The emerging role of class-3 semaphorins and their neuropilin receptors in oncology.The potential of class 3 semaphorins as both targets and therapeutics in cancer.Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of miceExtrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System.The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.The role of the semaphorins in cancer.Altering the intratumoral localization of macrophages to inhibit cancer progression.Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy.Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation.Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
P2860
Q26830075-CC6668BC-EBEB-4DC9-9A10-5151360A87D5Q26862741-79AC2E8D-052A-4132-8014-79231C1A8C04Q26991991-190409AE-FC1D-4256-9082-660D31BC0B2AQ27002903-DBB9718F-0271-45E9-83D7-EA6BA255D91CQ27003898-1A860D72-4C16-4E41-9156-86E333F0EA44Q28079015-4965327D-A48D-431B-8164-9DCF570F25F5Q33410375-D2756046-F981-4AA3-A66F-B912F2B4461AQ34548299-CB5172D4-5EB0-42D7-AC37-AF3E01482CDAQ34941883-61F171D5-246D-4F4F-A6E2-4AFF5E927017Q34978216-6F2C14A0-0AC3-4F81-9DBA-13AE62172008Q35653085-51BB58DF-FA14-4866-BBE1-22516A20AF30Q35742534-5383DAE4-7E8C-4914-A6BF-CCD2F5C70F79Q36159455-F9E5E45B-67B5-4D2B-B72B-6FAFFB24FE24Q36159478-686BF560-AC0B-44AB-B718-6118FC2A9AB9Q36283038-EE9821A4-6259-4DDD-B7BF-C188997186E3Q36296805-F1008FE5-AC36-4727-9A4B-DE0B493BA958Q36546773-FFC82BCD-E339-4666-B2DB-E94FCB380B8DQ36769616-F39195A6-5AD3-4718-B916-A236493C7F48Q36903131-0F21BC0F-8E91-4359-9411-760ED79EA50DQ36905839-52CEDC03-01CD-4A1F-A144-872E69CD87C0Q36941168-761BD876-23F3-48A5-8322-53524E7A1A7FQ37437544-23C759DF-0084-4F60-B5BF-1F91C8B67BF2Q37672654-E6009B5A-DE5E-423E-8A2E-D339968B024AQ37711201-24A4F14B-8D0C-4D3D-B353-EE4FB20ABBF5Q38029769-5EEB3C8C-0C30-4658-AADA-4FDBAA50A5B2Q38060665-C7065AAD-E705-4CB1-911E-2A29D97B26A3Q38066416-05EB8F1E-4072-4EEA-A1C0-D9E4A6F52DC3Q38082866-5EE8AA84-079E-4C0E-9E20-715135D5F20AQ38150356-8CE4019A-810C-438F-A54B-E09C67A4C0A6Q38256958-50FD7265-C548-4FD4-A292-5905129B2795Q38272709-330B4B06-0463-4A9C-80C8-8A78492EDC7BQ38645097-474EF482-43C2-4B03-A1FE-D68632615E3CQ38697928-26767E6F-F234-4D85-9F1A-489F22E7DA85Q38709705-BBA6D048-B89A-45A3-BB2B-CC5958669668Q38901012-C170140C-5F49-43C8-A1D7-77108DEBD68AQ38929961-19C6689C-88D1-44A2-B2E2-261455CBB904Q39173767-5787E79F-27B4-4A69-B212-6298F1820552Q39265746-68756C21-4941-4844-B43A-E525B3886F54Q39333626-869F7914-F4C9-4552-8EBC-084322FA2D25Q39345414-7557CCCA-A93A-4329-8EEA-ACB1D4547AA8
P2860
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Semaphorin 3A overcomes cancer ...... tiangiogenic treatment in mice
@ast
Semaphorin 3A overcomes cancer ...... tiangiogenic treatment in mice
@en
type
label
Semaphorin 3A overcomes cancer ...... tiangiogenic treatment in mice
@ast
Semaphorin 3A overcomes cancer ...... tiangiogenic treatment in mice
@en
prefLabel
Semaphorin 3A overcomes cancer ...... tiangiogenic treatment in mice
@ast
Semaphorin 3A overcomes cancer ...... tiangiogenic treatment in mice
@en
P2093
P2860
P50
P356
P1476
Semaphorin 3A overcomes cancer ...... tiangiogenic treatment in mice
@en
P2093
Donatella Regano
Lorena Zentilin
Stefania Capano
P2860
P304
P356
10.1172/JCI58976
P407
P577
2012-04-09T00:00:00Z